TY - JOUR
T1 - Targeting platelet receptor function in thrombus formation: The risk of bleeding
AU - Swieringa, Frauke
AU - Kuijpers, Marijke J. E.
AU - Heemskerk, Johan W. M.
AU - van der Meijden, Paola E. J.
PY - 2014/1
Y1 - 2014/1
N2 - In this review, we presume that the process of thrombus formation, as assessed in whole blood flow studies and in experimental (murine) thrombosis studies, reflects the platelet responses in human haemostasis and thrombosis. Following this concept, we give an up-to-date overview of the main platelet receptors and signalling pathways that contribute to thrombus formation and are used as targets in (pre)clinical intervention studies to prevent cardiovascular disease. Discussed are receptors for thrombin, thromboxane, ADP, ATP, prostaglandins, von Willebrand factor, collagen, CLEC-2 ligand, fibrinogen and laminin. Sketched are the consequences of receptor deficiency or blockage for haemostasis and thrombosis in mouse and man. Recording of bleeding due to (congenital) platelet dysfunction or (acquired) antiplatelet treatment occurs according to different protocols, while common laboratory methods are used to determine platelet function.
AB - In this review, we presume that the process of thrombus formation, as assessed in whole blood flow studies and in experimental (murine) thrombosis studies, reflects the platelet responses in human haemostasis and thrombosis. Following this concept, we give an up-to-date overview of the main platelet receptors and signalling pathways that contribute to thrombus formation and are used as targets in (pre)clinical intervention studies to prevent cardiovascular disease. Discussed are receptors for thrombin, thromboxane, ADP, ATP, prostaglandins, von Willebrand factor, collagen, CLEC-2 ligand, fibrinogen and laminin. Sketched are the consequences of receptor deficiency or blockage for haemostasis and thrombosis in mouse and man. Recording of bleeding due to (congenital) platelet dysfunction or (acquired) antiplatelet treatment occurs according to different protocols, while common laboratory methods are used to determine platelet function.
KW - Antiplatelet drugs
KW - Bleeding
KW - Cardiovascular disease
KW - Platelets
KW - Thrombus
U2 - 10.1016/j.blre.2013.12.001
DO - 10.1016/j.blre.2013.12.001
M3 - Article
C2 - 24411640
SN - 0268-960X
VL - 28
SP - 9
EP - 21
JO - Blood Reviews
JF - Blood Reviews
IS - 1
ER -